ARTHRALGIA Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for ARTHRALGIA

ARTHRALGIA treatment research studies

MEPROBAMATE clinical trials, surveys and public health registries

Find Drug Side Effect reports


Toxicity To Various Agents (14)
Respiratory Arrest (6)
Cardiac Arrest (6)
Pulmonary Oedema (5)
Completed Suicide (5)
Death (5)
Loss Of Consciousness (4)
Depressed Level Of Consciousness (3)
Excoriation (3)
Contusion (3)
Cardiovascular Insufficiency (3)
Aspiration (3)
Extrapyramidal Disorder (3)
Fall (3)
Suicide Attempt (3)
Respiratory Depression (3)
Pulmonary Congestion (3)
Hypothermia (3)
Pancreatitis Acute (3)
Circulatory Collapse (2)
Cardiomegaly (2)
Coma (2)
Dyspnoea (2)
Hypotension (2)
Drowning (2)
Convulsion (2)
Vomiting (2)
Malaise (2)
Injury (2)
Peripheral Ischaemia (2)
Oropharyngeal Pain (2)
Unresponsive To Stimuli (2)
Salivary Hypersecretion (2)
Neonatal Respiratory Distress Syndrome (1)
Normal Pressure Hydrocephalus (1)
Intentional Overdose (1)
Lung Disorder (1)
Obesity (1)
Left Ventricular Hypertrophy (1)
Laryngeal Disorder (1)
Intentional Self-injury (1)
Pneumonia (1)
Pain In Extremity (1)
Overdose (1)
Oedema Peripheral (1)
Pallor (1)
Pelvic Inflammatory Disease (1)
Portal Triaditis (1)
Poisoning (1)
Premature Baby (1)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

ARTHRALGIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Conditions: Arthralgia;   Breast Cancer;   Hot Flashes;   Musculoskeletal Complications;   Sexual Dysfunction
Interventions: Drug: therapeutic testosterone;   Other: placebo
Outcome Measures: The intra-patient change in joint pain at 3 months from baseline as measured by the Brief Pain Inventory for aromatase-inhibitor Arthralgias (BPI-AIA);   Safety and tolerability of transdermal testosterone assessed using Common Terminology Criteria for Adverse Events (CTCAE) 4.0 and additional questionnaires, including alopecia, acne, and hirsutism as reported by the patient;   The intra-patient change in joint pain and its interference of activity for each month from baseline as measured by BPI-AIA;   The change of hot flashes during the first two months from baseline as measured by hot flash diary;   The change of libido and menopause-specific quality of life from baseline as measured by MENQOL and POMS monthly
2 Recruiting Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors
Conditions: Arthralgia;   Breast Cancer
Interventions: Other: aromatase inhibition therapy - OBSERVATIONAL ONLY;   Other: medical chart review;   Other: questionnaire administration;   Procedure: assessment of therapy complications
Outcome Measures: Arthralgia incidence, defined as proportion of the baseline population (those who have taken ≥ 9 doses of aromatase inhibitor [AI]) in which new or worsening joint pain or stiffness is observed at 1, 3, and 12 months after beginning AI therapy;   Time to onset of Arthralgia (continuous variable in weeks) among baseline population;   Arthralgia point prevalence, defined as proportion of the baseline population with a score of ≥ 2 on any one dimension of the outcome measure at 1, 3, and 12 months after beginning AI therapy;   Symptom trajectories over the course of treatment;   Patient well-being: sleep quality, mood, and physical function
3 Recruiting Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone
Conditions: Arthralgia;   TMJ
Interventions: Drug: Methylprednisolone;   Drug: Physiologic saline
Outcome Measures: VAS pain score change at maximal mouth opening;   VAS pain score change at jaw rest;   Instrument measures;   Adverse events
4 Recruiting Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
Conditions: Joint Pain;   Breast Cancer
Intervention: Behavioral: Walk with Ease
Outcome Measures: Self-reported joint pain;   Self-reported walking
5 Not yet recruiting Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia
Conditions: Taxane;   Drug-related Side Effects and Adverse Reactions;   Pain;   Breast Cancer
Interventions: Drug: Pregabalin;   Drug: Placebo
Outcome Measures: Integrated Numeric Pain Scores and Rescue Analgesic Medication Requirement as calculated by the method proposed by Silverman et al (Silverman, O'Connor et al. 1993).;   Numeric Pain Score (NPS);   The additional number of hours spent in horizontal position (∆HHP**);   FACT-taxane score
6 Not yet recruiting Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis
Conditions: Psoriasis;   Arthralgia
Intervention: Other: Acupuncture
Outcome Measures: Pain measured on the VAS;   Improvement in life quality measured with the DLQI (Dermatology Life Quality Index);   Approvement in skin lesions
7 Recruiting Yoga for Aromatase Inhibitor-associated Joint Pain
Condition: Breast Cancer
Interventions: Other: Questionnaires;   Other: Yoga Classes
Outcome Measures: Rate of Study Enrollment;   Rate of Study Completion;   Occurrence of Reduced Pain Severity;   Occurrence of Relief from Other Side Effects
8 Unknown  CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
Conditions: Breast Neoplasms;   Arthralgia;   Arthritis;   Genetic Polymorphism
Intervention: Drug: Aromatase Inhibitor(Femara or Arimidex)
Outcome Measures: Change of SNPs (PCR & sequencing), Estrogen, Inflammatory Cytokine level;   EORTC (European Organization for Research and Treatment of Cancer)- QOL(Quality of Life)- C30, BR23 & Skeletal pain information, BMI
9 Recruiting RFN for SIJ Disease Study
Condition: Sacro Iliac Joint Pain
Intervention: Procedure: Comparison of active versus sham radiofrequency neurotomy with Simplicity III
Outcome Measures: Pain Intensity;   Quality of pain;   Health related Quality of life;   Anxiety and Depression;   Functional Disability;   Health related quality of life and quality-adjusted life years;   Portion of patients randomised to sham requiring rescue therapy with RFN
10 Recruiting S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions: Breast Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: duloxetine hydrochloride;   Other: placebo
Outcome Measures: Reduction in average joint pain according to BPI-SF assessed up to 12 weeks;   Reduction in worst joint pain according to the BPI-SF worst pain score assessed up to 12 weeks;   Reduction in pain interference according to the BPI-SF worst pain score assessed up to 12 weeks
11 Recruiting iFuse Implant System® Minimally Invasive Arthrodesis
Condition: Chronic, Disabling Sacroiliac Joint Pain
Interventions: Device: iFuse Implant System;   Other: Conservative Management
Outcome Measures: The change in lower back pain as rated by the study subject using a 0-100 visual analog scale (VAS) at 6 months after initiation of treatment;   Change from baseline in lower back pain (VAS);   Change from baseline in leg pain (VAS;   Change in disability due to back pain (ODI;   Change in quality of life (EQ-5D;   Change in ambulatory and work status;   Change in depression score (Zung Depression Scale;   Change in objective functional test (ASLR;   Change in walking distance;   Patient satisfaction and self-rating of disease state;   Serious adverse events;   Device breakage, loosening and migration
12 Recruiting Antibiotic Treatment of Multiple Erythema Migrans
Condition: Multiple Erythema Migrans
Interventions: Drug: ceftriaxone;   Drug: doxycycline;   Other: erythema migrans patients treated with doxycycline
Outcome Measures: Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, Arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.;   Comparison of subjective symptoms such as fatigue, malaise, Arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple erythema migrans and control subjects without a history of Lyme borreliosis.;   Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, Arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.
13 Recruiting Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections
Condition: Sacroiliac Joint Pain
Interventions: Drug: Intra-articular sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine);   Drug: Landmark guided sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine)
Outcome Measures: Pain score;   Oswestry disability index score;   Oswestry disability index
14 Unknown  Synvisc Injections for Lumbar Facet Joint Pain
Condition: Joint Pain
Intervention: Procedure: Synvisc viscosupplementation
Outcome Measures: Visual Analogue Scale (VAS) for baseline pain (best, worst, average) and pain while walking;   Oswestry Disability Questionnaire;   Short Form 36-Item (SF-36);   Standing/walking tolerance (defined as time patient can sit for before pain level reaches baseline or distance walked before pain reaches baseline);   Analgesic usage;   Lumbar range of motion;   Patient satisfaction
15 Recruiting High Dose Vitamin D vs Standard Dose Vitamin D Study
Condition: Breast Cancer
Interventions: Drug: 800 IU Vitamin D Supplement;   Drug: 50,000 IU Vitamin D supplement
Outcome Measures: Efficacy;   Compliance with Anti-Cancer Treatment
16 Recruiting Oral Contraceptive During Menopausal Transition
Condition: Perimenopause
Interventions: Drug: oral contraceptive;   Drug: NSAID
Outcome Measures: improvement in symptoms;   quality of life
17 Recruiting Context Effects in Exercise Therapy for Knee and/or Hip Pain
Conditions: Joint Pain;   Knee Pain;   Hip Pain;   Osteoarthritis, Knee;   Osteoarthritis, Hip
Interventions: Other: Contextually enhanced physical surroundings of exercise;   Other: Neuromuscular exercise
Outcome Measures: Patients' Global Perceived Effect;   Change from baseline in KOOS (The Knee injury and Osteoarthritis Outcome Score) or HOOS (The Hip Dysfunction and Osteoarthritis Score), respectively;   Change from baseline in The 36-item Short-Form Health Survey (SF-36);   Change from baseline in Arthritis Self-Efficacy Scale;   Patient satisfaction with physical surroundings
18 Recruiting Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
Conditions: Osteoarthritis;   Rheumatoid Arthritis;   Lower Back Pain;   Joint Pain;   Muscle Pain
Intervention: Drug: Buprenorphine transdermal patch
Outcome Measures: Efficacy according to BS-11 pain score;   Secondary efficacy outcome;   Adverse events
19 Recruiting The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.
Condition: Women With Estrogen Receptor Positive Breast Cancer Taking Aromatase Inhibitors (AI), Who Are Experiencing Joint Discomfort and Stiffness,
Interventions: Other: Arm A Directed exercise program;   Other: Observation
Outcome Measures: Pain Disability Index;   Plasma levels of inflammatory markers.
20 Recruiting Validity and Reliability of Diagnostic Findings of SI Joint Blocking
Condition: SI Joint Pain
Interventions: Drug: 0.75% bupivacaine;   Drug: .75% bupivacaine
Outcome Measures: Numeric Rating Scale;   Subgroup analysis by diagnosis at 1 month post 3rd block.